Genome Editing Market Size To Reach $24.99 Billion By 2030

Genome Editing Market Growth & Trends

The global genome editing market size is expected to reach USD 24.99 billion by 2030, exhibiting a CAGR of 17.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

 Request a free sample copy or view report summary: Genome Editing Market Report

Genome Editing Market Report Highlights

• By technology, the (CRISPR)/Cas9 segment held the highest share of 42.9% in 2022. It is due to an increased usage of CRISPR owing to its advantages such as targeted gene disruption

• Ex-vivo accounted for the dominant share of 52.6% in the delivery method segment in 2022. The dominant share is attributed to the growing high control offered by the model in DNA modification

• The genetic engineering segment dominated the global market in terms of application, due to the increasing number of gene therapy clinical trials

• By end-user, biotechnology and pharmaceutical companies segment held a major share of 51.2% in 2022 due to a growing number of research activities for novel therapeutic development within various biotechnology companies

• The contract-based segment dominated the market in 2022, due to the cost-effective services offered by contract service providers

• North America held a dominant share of 47.9% in 2022. The major reason is the presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region

• A few of the key players include Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis S.A.; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; and OriGene Technologies, Inc.

Genome Editing Market Segmentation

Grand View Research has segmented the global genome editing market based on technology, delivery method, application, mode, end-use, and region:

Genome Editing Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• (CRISPR)/Cas9

• TALENs/MegaTALs

• ZFN

• Meganucleases

• Others

Genome Editing Delivery Method Outlook (Revenue, USD Billion, 2018 - 2030)

• Ex-vivo

• In-vivo

Genome Editing Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Genetic Engineering

• Cell Line Engineering

• Animal Genetic Engineering

• Plant Genetic Engineering

• Others

• Clinical Applications

• Diagnostics

• Therapy Development

Genome Editing Mode Outlook (Revenue, USD Billion, 2018 - 2030)

• Contract

• In-house

Genome Editing End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Biotechnology & Pharmaceutical Companies

• Academic & Government Research Institutes

• Contract Research Organizations

Genome Editing Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait 

List of Key Players in the Genome Editing Market

• Merck KGaA

• Cibus, Recombinetics, Inc.

• Sangamo

• Editas Medicine

• Precision Biosciences

• CRISPR Therapeutics

• Intellia Therapeutics, Inc.

• Caribou Biosciences, Inc.

• Cellectis S.A.

• AstraZeneca

• Takara Bio USA

• Horizon Discovery Group plc

• Integrated DNA Technologies, Inc.

• Egenesis Inc.

• GenScript

• New England Biolabs

• OriGene Technologies, Inc.

• Lonza

• Thermo Fisher Scientific, Inc.